Outcomes for in-hospital mortality were compared between adult patients, women vs men, among those who had both acute myocardial infarction (AMI) and heart-related mechanical complications (MC).
Higher in-hospital mortality rates were seen among female patients vs male patients admitted to the hospital for an acute myocardial infarction (AMI) who then developed mechanical complications (MC), according to a poster1 presented at the recent American Society for Preventive Cardiology’s Congress on CVD Prevention, which was held in Arlington, Texas, July 21-23.
“Mechanical complications are rare, yet very serious complications of acute myocardial infarction,” the study authors wrote. “Data on the sex differences in characteristics and outcomes of AMI with MC are limited.”
Data from January 1, 2012, through December 31, 2020, came from the National In-Patient Sample on women 18 years and older with dual AMI and MC diagnoses. The primary outcome was sex differences for in-hospital mortality, and their secondary outcomes were differences in acute kidney injury (AKI), major bleeding, use of inotropes—medications that help the heart muscles adjust to contract harder or easier2—permanent pacemaker implantation (PPI), performance of percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), surgery (ventricular septal defect repair and mitral valve surgery), pericardiocentesis, mechanical circulatory support, ischemic stroke, and mechanical ventilation.
The female patients in this analysis had an older mean (SD) age of 72.0 (0.53) years vs 65.0 (0.40) for the male patients (P < .000), and there were 2 overall cohorts: 1,464,770 patients who had an ST-segment elevation MI (STEMI) and 3,739,574 who had non-STEMI (NSTEMI). Of these, 2915 in the STEMI group had MC and 629 in the NSTEMI group did not have MC. Sixty-two percent of the overall study population were male patients.
Overall, for in-hospital mortality, having MC vs not having MC led to a 39% higher rate among the female patients with AMI compared with male patients (adjusted odds ratio [aOR], 1.39; 95% CI, 1.079-1.798; P < .01), a 50% higher rate in the female patients who had a STEMI, and a 21% higher rate in those who had an NSTEMI. Further, among the female patients who had a STEMI without MC, the rate of in-hospital mortality was also elevated, by 13%. The most significant difference was seen between those who had an NSTEMI with or without complications: 21% higher rate vs a 10% reduced rate, respectively.
For the secondary outcomes investigated, the female patients who had an AMI with no MC had greater reduced rates of the following compared with those who had MC, respectively:
Among those who had a STEMI, not having MC vs having MC, respectively, correlated with greater reduced rates of in-hospital AKI (34% vs 7%), PCI (20% vs 14%), CABG (54% vs 50%), and mechanical ventilation (15% vs 11%). And for those who had an NSTEMI without MC, 28%, 8%, 23%, 22%, 55%, 20%, 20%, and 19% reduced risks were seen for vasopressor use, PPM, AKI, PCI, CABG, surgery, circulatory support, and mechanical ventilation, respectively.
Men were more likely overall to have AKI (P < .05) and to undergo CABG (P < .00), and women were more likely to have a stroke (P < .05) no matter their type of MI. The authors also determined that age older than 50 years and female sex, but only for those who had an AMI with MC, were independent predictors of in-hospital mortality (P < .00).
Reference
1. Rivera FB, Salva WF, Gonzales JS, et al. Sex differences in trends and outcomes of acute myocardial infarction with mechanical complications in the United States. Presented at: ASPC Congress on CVD Prevention; July 21-23, 2023; Arlington, Texas. Poster 181.
2. Inotropes. Cleveland Clinic. Updated May 17, 2022. Accessed July 27, 2023. https://my.clevelandclinic.org/health/treatments/23032-inotropes
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More